Abstract
The Kono-S anastomosis was introduced in 2011 as an alternative anastomosis in Crohn’s disease (CD) surgery. Since then, prevailing evidence of the favorable results of the Kono-S anastomosis has been published from around the world. We conducted this study to analyze the effectiveness of the Kono-S anastomosis, by searching Medline, Embase, CNKI, and google scholar. Binominal data were analyzed after Freeman–Tukey double-arcsine transformation. Comparative data were analyzed using the Mantel–Haenszel model for dichotomous outcomes and the mean difference for continuous outcomes. We identified 676 patients who underwent surgery with a Kono-S anastomosis. Surgical recurrence was pooled at an average of 0% (CI: 0.00–0.01) and a reduced mean Rutgeerts score of 1.375 (CI: 0.727–2.023) after Kono-S anastomosis. Endoscopic recurrence after sensitivity analysis was 5% (CI: 0.00–0.15). Complications were rare, with a 3% incidence of ileus (CI: 0.01–0.05), a 4% incidence of small bowel obstruction (CI: 0.01–0.10), a 1% incidence of an anastomotic leak incidence (CI: 0.00–0.03), and a 10% incidence of postoperative infection (CI: 0.03–0.20). Evidence from this meta-analysis favors the Kono-S anastomosis for CD patients, especially for ileocolic anastomosis. Thus, clinicians should consider the applicability of Kono-S anastomosis in respective institutions.
Similar content being viewed by others
References
Kono T, Ashida T, Ebisawa Y, Chisato N, Okamoto K, Katsuno H, et al. A new antimesenteric functional end-to-end handsewn anastomosis: surgical prevention of anastomotic recurrence in Crohn's disease. Dis Colon Rectum. 2011;54(5):586–92. https://doi.org/10.1007/DCR.0b013e318208b90f.
Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg. 2000;87(12):1697–701. https://doi.org/10.1046/j.1365-2168.2000.01589.x.
Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54(2):237–41. https://doi.org/10.1136/gut.2004.045294.
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009;136(2):441–450.e441. https://doi.org/10.1053/j.gastro.2008.10.051.
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99(4):956–63. https://doi.org/10.1016/0016-5085(90)90613-6.
Kano M, Hanari N, Gunji H, Hayano K, Hayashi H, Matsubara H. Is "functional end-to-end anastomosis" really functional? a review of the literature on stapled anastomosis using linear staplers. Surg Today. 2017;47(1):1–7. https://doi.org/10.1007/s00595-016-1321-9.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097–e10000971000097. https://doi.org/10.1371/journal.pmed.1000097.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. https://doi.org/10.1186/1471-2288-14-135.
Nyaga VN, Arbyn M, Aerts M. Metaprop: a stata command to perform meta-analysis of binomial data. Archives of Public Health. 2014;72(1):39. https://doi.org/10.1186/2049-3258-72-39.
Takeshima N, Sozu T, Tajika A, Ogawa Y, Hayasaka Y, Furukawa TA. Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference? BMC Med Res Methodol. 2014;14(1):30. https://doi.org/10.1186/1471-2288-14-30.
Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22(17):2693–710. https://doi.org/10.1002/sim.1482.
Harbord RM, Higgins JPT. Meta-regression in stata the stata journal. 2008;8(4):493–519. https://doi.org/10.1177/1536867X0800800403.
Shimada N, Ohge H, Kono T, Sugitani A, Yano R, Watadani Y, et al. Surgical recurrence at anastomotic site after bowel resection in Crohn's disease: comparison of Kono-S and end-to-end anastomosis. J Gastrointest Surg. 2019;23(2):312–9. https://doi.org/10.1007/s11605-018-4012-6.
Katsuno H, Maeda K, Hanai T, Masumori K, Koide Y, Kono T. Novel antimesenteric functional end-to-end handsewn (Kono-S) anastomoses for Crohn's disease: a report of surgical procedure and short-term outcomes. Dig Surg. 2015;32(1):39–44. https://doi.org/10.1159/000371857.
Luglio G, Rispo A, Imperatore N, Giglio MC, Amendola A, Tropeano FP, et al. Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's disease: the SuPREMe-CD study–a randomized clinical trial. Ann Surg. 2020. https://doi.org/10.1097/sla.0000000000003821.
Fichera A, Zoccali M, Kono T. Antimesenteric functional end-to-end handsewn (Kono-S) anastomosis. J Gastrointest Surg. 2012;16(7):1412–6. https://doi.org/10.1007/s11605-012-1905-7.
Lin D, Krane M, Umanskiy K, Rubin M, Rubin D, Hurst R, et al. Surgical prophylaxis of Crohn's disease recurrence: the Kono-S anastomosis. Preliminary results of a single-institution experience: P-52. Inflamm Bowel Dis. 2011;17(Suppl_2):S27–S2727. https://doi.org/10.1097/00054725-201112002-00089.
Krane MK, Cannon LM, Allaix Marco E, Kono T, Fichera A. A new antimesenteric functional end-to-end handsewn (Kono-S) anastomosis: feasibility and short-term outcomes in Crohn’s disease. J Am Coll Surg. 2015;221(4, Supplement 2):e5. https://doi.org/10.1016/j.jamcollsurg.2015.08.313.
Seyfried S, Post S, Kienle P, Galata CL. Die Kono-S-anastomose in der Chirurgie des Morbus Crohn. Der Chirurg. 2019;90(2):131–6. https://doi.org/10.1007/s00104-018-0668-4.
Kono T, Fichera A, Maeda K, Sakai Y, Ohge H, Krane M, et al. Kono-S Anastomosis for surgical Prophylaxis of anastomotic recurrence in Crohn's disease: an international multicenter study. J Gastrointest Surg. 2016;20(4):783–90. https://doi.org/10.1007/s11605-015-3061-3.
Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.
Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut. 2011;60(9):1178–81.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785–92.
Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7(2):77–90.
Patel KV, Darakhshan AA, Griffin N, Williams AB, Sanderson JD, Irving PM. Patient optimization for surgery relating to Crohn's disease. Nat Rev Gastroenterol Hepatol. 2016;13(12):707–19. https://doi.org/10.1038/nrgastro.2016.158.
Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590–605. https://doi.org/10.1016/s0140-6736(12)60026-9.
Machado WM, Miranda JRA, Morceli J, Padovani CR. The small bowel flora in individuals with cecoileal reflux. Arq Gastroenterol. 2008;45:212–8.
Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology. 1997;113(5):1767–78. https://doi.org/10.1053/gast.1997.v113.pm9352883.
Magro DO, Santos A, Guadagnini D, de Godoy FM, Silva SHM, Lemos WJF, et al. Remission in Crohn’s disease is accompanied by alterations in the gut microbiota and mucins production. Sci Rep. 2019;9(1):13263. https://doi.org/10.1038/s41598-019-49893-5.
Alhagamhmad MH, Day AS, Lemberg DA, Leach ST. An overview of the bacterial contribution to Crohn disease pathogenesis. J Med Microbiol. 2016;65(10):1049–59. https://doi.org/10.1099/jmm.0.000331.
Ikeuchi H, Kusunoki M, Yamamura T. Long-term results of stapled and hand-sewn anastomoses in patients with Crohn's disease. Dig Surg. 2000;17(5):493–6. https://doi.org/10.1159/000051946.
Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731–42. https://doi.org/10.1038/ajg.2013.287.
Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18(9):1617–23. https://doi.org/10.1002/ibd.21928.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015;385(9976):1406–17. https://doi.org/10.1016/S0140-6736(14)61908-5.
Panaccione R, Ghosh S. Optimal use of biologics in the management of Crohn's disease. Therap Adv Gastroenterol. 2010;3(3):179–89. https://doi.org/10.1177/1756283X09357579.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest Statement
None of the authors has any conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Ng, C.H., Chin, Y.H., Lin, S.Y. et al. Kono-S anastomosis for Crohn’s disease: a systemic review, meta-analysis, and meta-regression. Surg Today 51, 493–501 (2021). https://doi.org/10.1007/s00595-020-02130-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00595-020-02130-3